10074-G5: A Benchmark c-Myc Inhibitor for Cancer Research

Executive Summary: 10074-G5 is a small-molecule c-Myc inhibitor that blocks c-Myc/Max dimerization, a key step in oncogenic transcriptional regulation (product information). It demonstrates potent in vitro efficacy with IC50 values of 15.6 ± 1.5 μM (Daudi cells) and 13.5 ± 2.1 μM (HL-60 cells), and induces tumor regression in vivo at 20 mg/kg over 10 days. The compound is DMSO-soluble, provided at ≥98% purity by APExBIO, and supports a range of cancer research applications including apoptosis and cell cycle arrest assays. Recent evidence underscores the centrality of c-Myc in aggressive tumor phenotypes, as c-Myc/TERT/NFκB signaling drives epithelial-mesenchymal transition and cancer progression (García-Castillo et al., 2025).

Biological Rationale

c-Myc is a basic helix-loop-helix leucine zipper (bHLH-ZIP) transcription factor essential for cell cycle progression, growth, metabolism, differentiation, and apoptosis. Overexpression of c-Myc is linked to multiple cancer types, including prostate, pancreatic, lung, breast, colon cancers, B-cell lymphoma, and leukemias, often correlating with aggressive disease and poor prognosis (García-Castillo et al., 2025). Recent studies show that microRNAs such as miR-196a modulate c-Myc levels, reinforcing its role in the c-Myc/TERT/NFκB oncogenic axis that underpins tumor progression and epithelial-mesenchymal transition.

Mechanism of Action of 10074-G5

10074-G5 is a selective small-molecule inhibitor that binds to the c-Myc bHLH-ZIP domain, preventing its heterodimerization with Max. This blockade disrupts the transcriptional regulation of c-Myc target genes, leading to reduced c-Myc protein levels, cell cycle arrest, and apoptosis. At 10 μM, 10074-G5 effectively inhibits c-Myc/Max dimerization in cell-based models (APExBIO). In vivo, 10074-G5 administration (20 mg/kg, intravenous, daily for 10 days) suppresses tumor growth without affecting animal body weight.

Evidence & Benchmarks

• 10074-G5 inhibits c-Myc/Max dimerization at 10 μM, leading to marked reduction in c-Myc protein in Daudi and HL-60 cell lines (product information).
• IC50 values are 15.6 ± 1.5 μM (Daudi, B-cell lymphoma) and 13.5 ± 2.1 μM (HL-60, acute promyelocytic leukemia) under standard culture conditions (product data).
• In vivo, 20 mg/kg intravenous 10074-G5 for 10 days significantly suppresses Daudi xenograft tumor growth in C.B-17 SCID mice, with no adverse effect on body weight (APExBIO).
• c-Myc is a major driver of epithelial-mesenchymal transition and aggressiveness in cancer through the c-Myc/TERT/NFκB axis (García-Castillo et al., 2025).
• 10074-G5 is DMSO-soluble at ≥37.9 mg/mL, insoluble in water, and should be stored at -20°C (APExBIO).

This article updates and extends previous discussions by providing integrated protocol parameters and recent mechanistic insights from the latest peer-reviewed data, which clarify the role of c-Myc in tumor progression.

For a focused comparison of apoptosis assay design, see Targeting the c-Myc/Max Axis with 10074-G5, which emphasizes mechanistic application strategies, whereas this article provides a more comprehensive protocol and clinical outlook.

Applications, Limits & Misconceptions

10074-G5 is widely used in cancer research for apoptosis assays, cell cycle arrest studies, and tumor regression models. Its defined IC50 values in hematological malignancy models make it a reliable benchmark for functional screening. The compound's high purity (≥98%) and solubility profile enable reproducible results in in vitro and in vivo settings (APExBIO).

Common Pitfalls or Misconceptions

• 10074-G5 is not water-soluble; attempting to dissolve it in aqueous buffers will result in precipitation and loss of activity (APExBIO).
• Long-term storage of prepared solutions is not recommended due to stability concerns; always prepare fresh aliquots prior to use.
• 10074-G5 does not inhibit c-Myc expression directly, but prevents c-Myc/Max dimerization, which leads to reduced c-Myc protein stability.
• The compound is not validated for non-cancer-related pathways and should not be extrapolated to unrelated signaling processes.
• In vivo efficacy is demonstrated in SCID mice with Daudi xenografts; effects in other cancer models may vary and require empirical validation.

Workflow Integration & Parameters

Protocol Parameters

• Compound preparation: Dissolve 10074-G5 in DMSO at ≥37.9 mg/mL or in ethanol at ≥3.53 mg/mL (ultrasonic assistance recommended).
• Cell-based assays: Use 10 μM for c-Myc/Max dimerization inhibition in Daudi or HL-60 cells; incubate 24–48 hours for apoptosis or cell cycle analysis (product protocol).
• In vivo dosing: Administer 20 mg/kg intravenously, daily for 10 days in SCID mice with Daudi xenografts (APExBIO).
• Storage: Store solid compound at -20°C; avoid long-term storage of solutions.
• Purity: Use material with ≥98% purity for reproducible results.

For advanced scenario-driven workflow guidance, see this article, which details troubleshooting and sensitivity optimization for apoptosis and tumor regression assays using 10074-G5.

Conclusion & Outlook

10074-G5 is a rigorously validated small-molecule c-Myc/Max dimerization inhibitor, enabling reproducible cell cycle arrest, apoptosis, and tumor regression studies. Its mechanism directly addresses the c-Myc/TERT/NFκB axis now recognized as central to aggressive cancer phenotypes (García-Castillo et al., 2025). APExBIO's high-purity supply, complete documentation, and clear protocol guidelines support its adoption in advanced cancer research workflows. Future work should refine its use in additional solid tumor models and explore combination therapies strictly within the c-Myc-related axis, as supported by the current evidence.